The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome

Yıl 2019, Cilt: 46 Sayı: 2, 195 - 200, 11.06.2019

İlknur Col Madendag Yusuf Madendag , Mehmet Ak Erdem Sahin Mefkure Eraslan Sahin

https://doi.org/10.5798/dicletip.539903

Öz

Objective:
It was aimed to investigate whether or not nuchal translucency(NT) thickness,
maternal serum free beta-human chorionic gonadotropin(β-hCG) and
pregnancy-associated plasma protein-A(PAPP-A) levels may affected by the use of
oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed
to evaluate pregnancy outcome in pregnant women using OMP.

Method:
This study was performed retrospectively including 1192 pregnant women, between
January 2015 and August 2017. Body mass index(BMI), maternal and gestational
age, levels of maternal serum PAPP-A and free β-hCG, NT measurement and the
crown–rump length(CRL), fetal sex, fetal birth weight, Apgar score
5thminute<7 and admission to neonatal intensive care unit(NICU) were
evaluated.

Results:
Maternal characteristics, ultrasound and biochemical parameters, fetal characteristics
and neonatal outcome were evaluated. There was no statistically significant
difference for maternal age, BMI, gestational age, PAPP-A, β-hCG, CRL, NT
thickness, fetal sex, fetal birth weight, Apgar score 5th minute <7 and the
number of admission to NICU during the first 28 days.

Conclusions:
Our results suggest that in clinical practice, 1) it seems that using OMP
cannot affect on NT, CRL and birth weight. 2) OMP cannot adversely affect on
production of PAPP-A and β-hCG in vivo. 3) NT, serum PAPP-A and β-hCG levels
and MoM values, which are markers of the first trimester screening test, do not
change by using OMP. Therefore using OMP cannot affect reliability of the first
trimester screening test in pregnancy with threatened abortion. 4) OMP does not
look like adversely affect on poor neonatal outcome.

Anahtar Kelimeler

Nuchal translucency measurement, prenatal diagnosis, progesterone, threatened abortion

Kaynakça

• 1. Alldred SK, Takwoingi Y, Guo B, et all. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Cochrane Database of Systematic Reviews 2017: 3.
• 2. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005; 25: 221–6.
• 3. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod. 2001; 16: 501–1504.
• 4. Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions. Best Pract Res Clin Obstet Gynaecol. 2008; 22: 375-89.
• 5. Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. Brid Med J. 2004; 329: 152.
• 6. Czajkowski K, Sienko J, Mogilinski M, et all. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007; 87: 613.
• 7. Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190: 745.
• 8. Alp M, Diclehan O. Tekrarlayan spontan abortusları olan çiftlerde genetik araştırmalar. Dicle Tıp Derg. 2006; 33: 71-80.
• 9. Dunn CL, Kelly RW, Critchley HO. Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reprod Biomed Online. 2003;7: 151.
• 10. Turgal M, Aydin E, Ozyuncu O. Effect of micronized progesterone on fetal‐placental volume in first‐trimester threatened abortion. J Clin Ultrasound. 2017; 45: 14-9.
• 11. Wang J, Liu S, Qin HM, Zhao Y, Wang XQ, and Yan Q. Pregnancy-associated plasma protein A up-regulated by progesterone promotes adhesion and proliferation of trophoblastic cells. Int J Clin Exp path. 2014; 7: 1427-37.
• 12. Giorlandino C, Cignini P, Padula F, et all. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. Am J Obstet Gynecol. 2015; 212: 335-e1.
• 13. Keçecioğlu M, Tokmak A, Keçecioğlu TS, et all. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage? Ginekol pol. 2016; 87: 390-4.
• 14. Kalem MN, Kalem Z, Bakırarar B, Ergün A, Gürgan T. The effect of progesterone use in the first trimester on fetal nuchal translucency. J Turk Ger Gynecol Assoc. 2018; 19: 29.